Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

I hope the shorts are loading up.

Excerpt from STAT article posted on Tuesday at thefly.com:

"Aurinia CEO says VOS could become blockbuster treatment, STATNews reports Though Aurinia Pharmaceuticals' (AUPH) VOS dry-eye drug trial failed on tolerability, its primary goal, the medicine proved to be more effective -- but slightly less tolerable -- than Allergan's (AGN) Restasis. Aurinia CEO Richard Glickman told STATNews in a phone interview that beating Restasis in efficacy means VOS could become a blockbuster treatment for dry-eye syndrome, saying "We knocked the efficacy out of the park with VOS... We're really excited but I guess I'll need to explain why to the market tomorrow."

I can't help but think that the outstanding/astounding VOS DES efficacy results have been noticed by Allergan (AGN) and other BP's.

Don't a lot of biotech buyouts happen after P2?

Isn't there a good chance that one or more BP's will be contacting Aurinia (if they haven't already)?